Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not going anywhere. Your not seeing the big picture. If you have done your DD on this company, you would understand this is part of the up listing. This is not a dilutive cash raise or an ordinary reverse split to screw shareholders.
$TOMDF 6k out! Do you believe yet? Up listing to the #nasdaq CM MARKET second quarter ??voting in May for share consolidation ?? ir.stockpr.com/todosmedical/s…
$TOMDF 6k out! Do you believe yet? Up listing to the #nasdaq CM MARKET second quarter 🔥voting in May for share consolidation 🔥 https://t.co/kD5JLtUlyX
— Randylus (@randylus) April 14, 2020
$TOMDF Sleeper Pure Play Diagnostics Company. #COVID19 #coronavirus #RapidTestKit #TestingForCovid19
$TOMDF Sleeper Pure Play Diagnostics Company. #COVID19 #coronavirus #RapidTestKit #TestingForCovid19 https://t.co/pTsGvr3MCK
— Boudin (@boudin420) April 13, 2020
$TOMDF Todos Medical Expands on Coronavirus (COVID-19) Distribution Agreement with Shanghai Liangrun Subsidiary Gibraltar. Dr. Joseph Wee, CEO of Todos Singapore, will lead Asian commercialization effort. investor.todosmedical.com/company-inform…
$TOMDF Todos Medical Expands on Coronavirus (COVID-19) Distribution Agreement with Shanghai Liangrun Subsidiary Gibraltar. Dr. Joseph Wee, CEO of Todos Singapore, will lead Asian commercialization effort. https://t.co/1d2dJJsRVL pic.twitter.com/kOAbxYTlOU
— Randylus (@randylus) April 11, 2020
Filings source link: https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001645260&action=getcompany
$TOMDF Chief Business Officer, Co-founder. Mr. Zigdon has been recognized for his leadership in the development and implementation of effective product development strategies and FDA submissions. #cancer #BreastCancerAwareness #Alzheimers #coronavirustest
$TOMDF Chief Business Officer, Co-founder. Mr. Zigdon has been recognized for his leadership in the development and implementation of effective product development strategies and FDA submissions. #cancer #BreastCancerAwareness #Alzheimers #coronavirustest pic.twitter.com/QN1jnsxkkl
— Randylus (@randylus) April 11, 2020
Strong buy and hold.
$TOMDF #bullish #coronavirustesting #BreastCancerAwareness
— Randylus (@randylus) April 10, 2020
13g out. Strategic Investment Holdings, LLC Reporting ownership of 13,008,976 shares for aggregate total owned of 30,100,072 shares. Percent of class 17.29% https://t.co/ry3B6XJpmx
Need flash people. This company is uplifting to the nasdaq. If your here to play some virus testing news, I suggest you hold your shares. That is all.
$TOMDF #bullish #coronavirustesting #BreastCancerAwareness
— Randylus (@randylus) April 10, 2020
13g out. Strategic Investment Holdings, LLC Reporting ownership of 13,008,976 shares for aggregate total owned of 30,100,072 shares. Percent of class 17.29% https://t.co/ry3B6XJpmx
If you are viewing this on mobile, it may be all run together without paragraph formatting. Best to view on a desktop or laptop where the formatting is correct. Good luck to all - feed back encouraged. randy
The following are the CONTINGENT VALUE RIGHTS AGREEMENT and links to SEC Filings for;
Ligand pharmaceuticals Inc. (LGND) Nasdaq - FORM 8-K January 27, 2010
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/d8k.htm
There is an individual SEC filing for the "Roche Contingent Value Rights Agreement"
LGNDZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex101.htm
Roche Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
Roche CVR. The Roche CVR Agreement entitles each holder of a Roche CVR to receive a pro rata portion of 65% of any milestone payments or 68% of any royalties paid by Roche under Metabasis’ partnered drug development program with Roche in hepatitis C, or 65% of the net proceeds of any sale of those program rights.
If you are interested in the other (3) CRV's associated with the Ligand Pharmaceuticals Acquisition of Metabasis Therapeutics, Inc. on January 28, 2010, they are list on the https://investorshub.advfn.com/Biotech-CVR-Plays-37758/
Good luck. Randy - Feedback encouraged.
The following are the CONTINGENT VALUE RIGHTS Agreements and links to SEC Filings for;
Ligand pharmaceuticals Inc. (LGND) Nasdaq - FORM 8-K January 27, 2010
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/d8k.htm
There is an individual SEC filing for each CRV below as well.
LGNDZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex101.htm
Roche Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
Roche CVR. The Roche CVR Agreement entitles each holder of a Roche CVR to receive a pro rata portion of 65% of any milestone payments or 68% of any royalties paid by Roche under Metabasis’ partnered drug development program with Roche in hepatitis C, or 65% of the net proceeds of any sale of those program rights.
=================
The following are CRV's from the Acquisition of Metabasis Therapeutics, Inc. on January 28, 2010
News Release on the Merger Completion of ligand and Metabasis Therapeutics, Inc.,: https://www.businesswire.com/news/home/20100128005321/en/Ligand-Completes-Acquisition-Metabasis
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/0001193125-10-015242-index.htm
LGNZZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex102.htm
TR Beta Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
TR Beta CVR. The TR Beta CVR Agreement entitles each holder of a TR Beta CVR to receive a pro rata portion of a percentage of the net proceeds of any license or sale of Metabasis’ Thyroid Receptor Beta program in hyperlipidemia: 50% of such net proceeds if the licensing/sale transaction occurs by the sixth anniversary of the Merger; 40% if in the seventh year after the Merger; 30% if in the eighth year after the Merger; or 20% if in the ninth or tenth year after the Merger.
LGNXZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex103.htm
Glucagon Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
Glucagon CVR. The Glucagon CVR Agreement entitles each holder of a Glucagon CVR to receive a pro rata portion of a percentage of the net proceeds of any license or sale of Metabasis’ glucagon receptor antagonist program in diabetes: 50% of such net proceeds if the licensing/sale transaction occurs by the sixth anniversary of the Merger; 40% if in the seventh year after the Merger; 30% if in the eighth year after the Merger; or 20% if in the ninth or tenth year after the Merger.
https://www.businesswire.com/news/home/20100128005321/en/Ligand-Completes-Acquisition-Metabasis
LGNYZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm
General Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
General CVR. The General CVR Agreement entitles each holder of a General CVR to receive a pro rata portion of cash payments equal to the shortfall, if any, from defined spending thresholds of Ligand’s funding of further research and development of drug development programs acquired from Metabasis. The basic threshold is $8 million of funding within the first 42 months after the Merger. A secondary threshold (which shall be waived in certain circumstances) is $7 million of funding within the first 30 months after the Merger.
$LGNDZ #remdesivir #coronavirus #covid19 #Infectiousdiseases Ligand Roche Contingent Value Rights
https://bioworld.com/COVID19products
https://twitter.com/randylus/status/1246871688580644864?s=20
Roche Collaboration to develop and commercialize therapies for neurological diseases. The collaboration provides research funding, potential milestone payments of up to $274 million and tiered royalty payments should a drug be commercialized.
https://fintel.io/doc/sec-lgnd-8k-ligand-pharmaceuticals-2020-april-02-18354
Rights - Roche Contingent Value Rights @Ligand_LGND <Nasdaq Ligand twitter
https://twitter.com/randylus/status/1246821047543820293?s=21
Info. Not a recommendation to buy or sell. For research purposes.
Nasdaq - LGND / Ligand Pharmaceuticals Incorporated
OTC Market CRV's (warrants)
---------
LGNDZ / Ligand Pharmaceuticals Incorporated Roche Contingent Value
LGNZZ / Ligand Pharmaceuticals Incorporated Beta Contingent Value
LGNYZ / Ligand Pharmaceuticals Incorporated General Contingent Value
LGNXZ / Ligand Pharmaceuticals Incorporated Glucagon Contingent Value
https://fintel.io/s/us/lgndz
LGND - Ligand Pharmaceuticals Incorporated OTC CRV's Pictured as of Close Friday 4/2/2020
Via @NPR: Might The Experimental Drug Remdesivir Work Against COVID-19? #remdesivirhttps://t.co/8gSgMS58TD
— Ligand (@Ligand_LGND) March 21, 2020
https://twitter.com/randylus/status/1246522483303309313?s=20
Ligand Pharmaceuticals Inc. Roche Contingent Value Rights $LGNDZ #catalysts #bullish
https://endpts.com/ligand-buys-its-way-into-partnership-with-roche-cf-foundation-plus-some-ion-channel-tech-once-owned-by-pfizer/
Smart money!
People like you are responsible for giving iHub a bad reputation. Your comment is false. This is not a sell off.
Up 150% since yesterday. Whatever you think. Your comment is not even close to reality.
Buy some for me. I’m out of powder.
Nothing happens between 10:30 and 3:00 EST.
Whatever.
Yeah this is a solid investment. I just rely on my DD. I have done my homework.
Whatever.
Not in this for #coronavirustesting alone. This is a great investment. Ignore the intraday price swings and talk a walk or read a magazine.
Congratulations to Dr. Paula Trzepacz, CMO of our joint venture Breakthrough Diagnostics, for receiving the @Investacure Cure Coin Award for her work in clinical development of therapeutics and diagnostics for #Alzheimers disease and other neurocognitive disorders.
$TOMDF #Alzheimers #BiomedicalScience https://t.co/1WR4yjFxoy
— Randylus (@randylus) March 20, 2020